It was a pleasure to talk to Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College, London, UK) around his recent analysis of the NAVIGATOR data, investigating the effect of tezepelumab in OCS-dependent severe asthma patients (Clinical Trial Identifier: NCT03347279).
The abstract ‘Effect of Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma: Results From the Phase 3 NAVIGATOR Study.‘ (ABSTRACT NUMBER: A1442) was presented at ATS 2021 International Conference, 14-19 May, 2021.
Questions
- What adverse events are associated with long-term maintenance oral corticosteroids (mOCS) in patients with severe asthma and how does this impact on quality of life and healthcare costs? (0:10)
- What is the rationale for the use of tezepelumab in the treatment of patients with severe asthma? (1:16)
- What have the PATHWAY and NAVIGATOR studies taught us about the efficacy and safety of tezepelumab in this indication? (2:06)
- Could you tell us a little about the objectives and design of your recent analysis of the NAVIGATOR data? (2:45)
- What were the findings of this analysis and what are their implications for patients with severe, OCS-dependent asthma? (3:36)
Disclosures: Andrew Menzies-Gow has participated in research with Astra Zeneca for which his institution has been renumerated and attended advisory boards, has consultancy agreements with and received speaker fees from Astra Zeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATS 2021 (Virtual).
